Dateline City:
WHITEHOUSE STATION, N.J.
KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer
Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data on the investigational
use of KEYTRUDA (pembrolizumab) the companys anti-PD-1
therapy in PD-L1 positive, advanced urothelial cancer (also known as
bladder cancer).
Language:
English
Contact:
MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more